Mersana Therapeutics Inc (NASDAQ: MRSN) is -20.26% lower on its value in year-to-date trading and has touched a low of $1.07 and a high of $6.28 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRSN stock was last observed hovering at around $1.80 in the last trading session, with the day’s gains setting it 0.05%.
Currently trading at $1.85, the stock is 5.44% and 8.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 2.78% at the moment leaves the stock -34.30% off its SMA200. MRSN registered 48.00% gain for a year compared to 6-month loss of -58.80%. The firm has a 50-day simple moving average (SMA 50) of $1.7068 and a 200-day simple moving average (SMA200) of $2.814975.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 18.59% gain in the last 1 month and extending the period to 3 months gives it a -7.27%, and is -15.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.78% over the week and 9.95% over the month.
Mersana Therapeutics Inc (MRSN) has around 123 employees, a market worth around $226.94M and $29.94M in sales. Profit margin for the company is -349.98%. Distance from 52-week low is 73.71% and -70.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-364.47%).
Mersana Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.17 with sales reaching $7.53M over the same period.The EPS is expected to grow by 53.15% this year, but quarterly earnings will post -31.20% year-over-year. Quarterly sales are estimated to shrink -2.20% in year-over-year returns.
158.0 institutions hold shares in Mersana Therapeutics Inc (MRSN), with institutional investors hold 95.94% of the company’s shares. The shares outstanding are 120.71M, and float is at 90.23M with Short Float at 11.42%. Institutions hold 94.64% of the Float.
The top institutional shareholder in the company is ECOR1 CAPITAL, LLC with over 19.36 million shares valued at $38.92 million. The investor’s holdings represent 15.9479 of the MRSN Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 11.33 million shares valued at $22.77 million to account for 9.3292 of the shares outstanding. The other top investors are NEXTECH INVEST LTD. which holds 9.53 million shares representing 7.8453 and valued at over $19.15 million, while BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC holds 7.135 of the shares totaling 8.66 million with a market value of $17.41 million.
Mersana Therapeutics Inc (MRSN) Insider Activity
The most recent transaction is an insider sale by Huber Martin H. Jr., the company’s President, CEO. SEC filings show that Huber Martin H. Jr. sold 50,423 shares of the company’s common stock on Sep 12 ’24 at a price of $1.76 per share for a total of $88744.0. Following the sale, the insider now owns 0.12 million shares.
Still, SEC filings show that on Jan 16 ’24, Protopapas Anna (Director) disposed off 29,399 shares at an average price of $2.71 for $79671.0. The insider now directly holds 125,153 shares of Mersana Therapeutics Inc (MRSN).
